Aquestive Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Aquestive Therapeutics, Inc. (AQST) reported Increase (Decrease) in Deferred Revenue of -$545.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-11
- Aquestive Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$273.00K, a 216.17% decline year-over-year.
- Aquestive Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$272.00K.
- Aquestive Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$272.00K.
- Aquestive Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$273.00K.
- Aquestive Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$571.00K.
- Aquestive Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$12.84M, a 1429.50% decline from fiscal 2023.
- Aquestive Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was $966.00K, a 96.14% decline from fiscal 2022.
- Aquestive Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was $25.04M, a 603.26% increase from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$545.00K 10-Q · filed 2026-08-11 | -$817.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$272.00K 10-Q · filed 2026-05-13 | -$544.00K derived: sum of 2 quarters · filed 2026-05-13 | -$817.00K derived: sum of 3 quarters · filed 2026-05-13 | -$582.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$272.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$545.00K derived: sum of 2 quarters · filed 2026-03-04 | -$310.00K derived: sum of 3 quarters · filed 2026-08-11 | -$571.00K 10-K · filed 2026-03-04 |
| 2025-09-30 | -$273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$38.00K derived: sum of 2 quarters · filed 2026-08-11 | -$299.00K 10-Q · filed 2025-11-05 | -$560.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $235.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$26.00K 10-Q · filed 2026-08-11 | -$287.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.78M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$261.00K 10-Q · filed 2026-05-13 | -$522.00K derived: sum of 2 quarters · filed 2026-05-13 | -$2.01M derived: sum of 3 quarters · filed 2026-05-13 | -$12.72M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$261.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$1.75M derived: sum of 2 quarters · filed 2026-03-04 | -$12.46M derived: sum of 3 quarters · filed 2026-03-04 | -$12.84M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$12.19M derived: sum of 2 quarters · filed 2025-11-05 | -$12.58M 10-Q · filed 2025-11-05 | -$14.05M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$10.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$11.09M 10-Q · filed 2025-08-11 | -$12.57M derived: sum of 3 quarters · filed 2025-08-11 | -$14.31M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$388.00K 10-Q · filed 2025-05-12 | -$1.86M derived: sum of 2 quarters · filed 2025-05-12 | -$3.60M derived: sum of 3 quarters · filed 2025-05-12 | -$4.30M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$3.22M derived: sum of 2 quarters · filed 2025-03-05 | -$3.91M derived: sum of 3 quarters · filed 2025-03-05 | $966.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | -$1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$2.44M derived: sum of 2 quarters · filed 2024-11-04 | $2.44M 10-Q · filed 2024-11-04 | $16.97M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | -$692.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.18M 10-Q · filed 2024-08-06 | $18.72M derived: sum of 3 quarters · filed 2024-08-06 | $22.02M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $4.87M 10-Q · filed 2024-05-07 | $19.41M derived: sum of 2 quarters · filed 2024-05-07 | $22.71M derived: sum of 3 quarters · filed 2024-05-07 | $22.32M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $14.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $17.84M derived: sum of 2 quarters · filed 2024-03-05 | $17.44M derived: sum of 3 quarters · filed 2024-03-05 | $25.04M 10-K · filed 2024-03-05 |
| 2022-09-30 | $3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $2.91M derived: sum of 2 quarters · filed 2023-11-06 | $10.51M 10-Q · filed 2023-11-06 | $10.31M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $7.20M 10-Q · filed 2023-08-07 | $7.01M derived: sum of 3 quarters · filed 2023-08-07 | $8.10M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $7.60M 10-Q · filed 2023-05-02 | $7.41M derived: sum of 2 quarters · filed 2023-05-02 | $8.50M derived: sum of 3 quarters · filed 2023-05-02 | $10.35M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | -$196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $894.00K derived: sum of 2 quarters · filed 2023-03-31 | $2.75M derived: sum of 3 quarters · filed 2023-03-31 | $3.56M 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $2.95M derived: sum of 2 quarters · filed 2022-11-01 | $3.76M 10-Q · filed 2022-11-01 | $3.67M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $2.67M 10-Q · filed 2022-08-02 | $2.58M derived: sum of 3 quarters · filed 2022-08-02 | $2.32M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $810.00K 10-Q · filed 2022-05-04 | $720.00K derived: sum of 2 quarters · filed 2022-05-04 | $466.00K derived: sum of 3 quarters · filed 2022-05-04 | $264.00K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$344.00K derived: sum of 2 quarters · filed 2022-03-08 | -$546.00K derived: sum of 3 quarters · filed 2022-03-08 | -$828.00K 10-K · filed 2022-03-08 |
| 2020-09-30 | -$254.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$456.00K derived: sum of 2 quarters · filed 2021-11-02 | -$738.00K 10-Q · filed 2021-11-02 | $1.45M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | -$202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$484.00K 10-Q · filed 2021-08-03 | $1.71M derived: sum of 3 quarters · filed 2021-08-03 | $1.80M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | -$282.00K 10-Q · filed 2021-05-04 | $1.91M derived: sum of 2 quarters · filed 2021-05-04 | $2.01M derived: sum of 3 quarters · filed 2021-05-04 | $1.77M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $2.29M derived: sum of 2 quarters · filed 2021-03-09 | $2.05M derived: sum of 3 quarters · filed 2021-03-09 | $1.60M 10-K · filed 2021-03-09 |
| 2019-09-30 | $96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$143.00K derived: sum of 2 quarters · filed 2020-11-04 | -$591.00K 10-Q · filed 2020-11-04 | -$651.00K derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | -$239.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$687.00K 10-Q · filed 2020-08-04 | -$747.00K derived: sum of 3 quarters · filed 2020-08-04 | -$1.20M derived: sum of 4 quarters · filed 2020-08-04 |
| 2019-03-31 | -$448.00K 10-Q · filed 2020-05-05 | -$508.00K derived: sum of 2 quarters · filed 2020-05-05 | -$961.00K derived: sum of 3 quarters · filed 2020-05-05 | -$897.00K derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-31 | -$60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$513.00K derived: sum of 2 quarters · filed 2020-03-11 | -$449.00K derived: sum of 3 quarters · filed 2020-03-11 | -$626.00K 10-K · filed 2020-03-11 |
| 2018-09-30 | -$453.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$389.00K derived: sum of 2 quarters · filed 2019-11-05 | -$566.00K 10-Q · filed 2019-11-05 | -$987.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $64.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$113.00K 10-Q · filed 2019-08-06 | -$534.00K derived: sum of 3 quarters · filed 2019-08-06 | -$7.00K derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | -$177.00K 10-Q · filed 2019-05-08 | -$598.00K derived: sum of 2 quarters · filed 2019-05-08 | -$71.00K derived: sum of 3 quarters · filed 2019-05-08 | |
| 2017-12-31 | -$421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $106.00K derived: sum of 2 quarters · filed 2019-03-14 | $545.00K 10-K · filed 2019-03-14 | |
| 2017-09-30 | $527.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $966.00K 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $439.00K 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |